PubMed:28473469
Annnotations
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-113 | Sentence | denotes | An engineered cyclic peptide alleviates symptoms of inflammation in a murine model of inflammatory bowel disease. |
| T2 | 114-241 | Sentence | denotes | Inflammatory bowel diseases (IBDs) are a set of complex and debilitating diseases for which there is no satisfactory treatment. |
| T3 | 242-344 | Sentence | denotes | Recent studies have shown that small peptides show promise for reducing inflammation in models of IBD. |
| T4 | 345-528 | Sentence | denotes | However, these small peptides are likely to be unstable and rapidly cleared from the circulation, and therefore, if not modified for better stability, represent non-viable drug leads. |
| T5 | 529-687 | Sentence | denotes | We hypothesized that improving the stability of these peptides by grafting them into a stable cyclic peptide scaffold may enhance their therapeutic potential. |
| T6 | 688-877 | Sentence | denotes | Using this approach, we have designed a novel cyclic peptide that comprises a small bioactive peptide from the annexin A1 protein grafted into a sunflower trypsin inhibitor cyclic scaffold. |
| T7 | 878-952 | Sentence | denotes | We used native chemical ligation to synthesize the grafted cyclic peptide. |
| T8 | 953-1212 | Sentence | denotes | This engineered cyclic peptide maintained the overall fold of the naturally occurring cyclic peptide, was more effective at reducing inflammation in a mouse model of acute colitis than the bioactive peptide alone, and showed enhanced stability in human serum. |
| T9 | 1213-1397 | Sentence | denotes | Our findings suggest that the use of cyclic peptides as structural backbones offers a promising approach for the treatment of IBD and potentially other chronic inflammatory conditions. |
Inflammaging
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-113 | Sentence | denotes | An engineered cyclic peptide alleviates symptoms of inflammation in a murine model of inflammatory bowel disease. |
| T2 | 114-241 | Sentence | denotes | Inflammatory bowel diseases (IBDs) are a set of complex and debilitating diseases for which there is no satisfactory treatment. |
| T3 | 242-344 | Sentence | denotes | Recent studies have shown that small peptides show promise for reducing inflammation in models of IBD. |
| T4 | 345-528 | Sentence | denotes | However, these small peptides are likely to be unstable and rapidly cleared from the circulation, and therefore, if not modified for better stability, represent non-viable drug leads. |
| T5 | 529-687 | Sentence | denotes | We hypothesized that improving the stability of these peptides by grafting them into a stable cyclic peptide scaffold may enhance their therapeutic potential. |
| T6 | 688-877 | Sentence | denotes | Using this approach, we have designed a novel cyclic peptide that comprises a small bioactive peptide from the annexin A1 protein grafted into a sunflower trypsin inhibitor cyclic scaffold. |
| T7 | 878-952 | Sentence | denotes | We used native chemical ligation to synthesize the grafted cyclic peptide. |
| T8 | 953-1212 | Sentence | denotes | This engineered cyclic peptide maintained the overall fold of the naturally occurring cyclic peptide, was more effective at reducing inflammation in a mouse model of acute colitis than the bioactive peptide alone, and showed enhanced stability in human serum. |
| T9 | 1213-1397 | Sentence | denotes | Our findings suggest that the use of cyclic peptides as structural backbones offers a promising approach for the treatment of IBD and potentially other chronic inflammatory conditions. |
| T1 | 0-113 | Sentence | denotes | An engineered cyclic peptide alleviates symptoms of inflammation in a murine model of inflammatory bowel disease. |
| T2 | 114-241 | Sentence | denotes | Inflammatory bowel diseases (IBDs) are a set of complex and debilitating diseases for which there is no satisfactory treatment. |
| T3 | 242-344 | Sentence | denotes | Recent studies have shown that small peptides show promise for reducing inflammation in models of IBD. |
| T4 | 345-528 | Sentence | denotes | However, these small peptides are likely to be unstable and rapidly cleared from the circulation, and therefore, if not modified for better stability, represent non-viable drug leads. |
| T5 | 529-687 | Sentence | denotes | We hypothesized that improving the stability of these peptides by grafting them into a stable cyclic peptide scaffold may enhance their therapeutic potential. |
| T6 | 688-877 | Sentence | denotes | Using this approach, we have designed a novel cyclic peptide that comprises a small bioactive peptide from the annexin A1 protein grafted into a sunflower trypsin inhibitor cyclic scaffold. |
| T7 | 878-952 | Sentence | denotes | We used native chemical ligation to synthesize the grafted cyclic peptide. |
| T8 | 953-1212 | Sentence | denotes | This engineered cyclic peptide maintained the overall fold of the naturally occurring cyclic peptide, was more effective at reducing inflammation in a mouse model of acute colitis than the bioactive peptide alone, and showed enhanced stability in human serum. |
| T9 | 1213-1397 | Sentence | denotes | Our findings suggest that the use of cyclic peptides as structural backbones offers a promising approach for the treatment of IBD and potentially other chronic inflammatory conditions. |
mondo_disease
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 52-64 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
| T2 | 86-112 | Disease | denotes | inflammatory bowel disease | http://purl.obolibrary.org/obo/MONDO_0005265 |
| T3 | 114-141 | Disease | denotes | Inflammatory bowel diseases | http://purl.obolibrary.org/obo/MONDO_0005265 |
| T4 | 143-147 | Disease | denotes | IBDs | http://purl.obolibrary.org/obo/MONDO_0005265 |
| T5 | 314-326 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
| T6 | 340-343 | Disease | denotes | IBD | http://purl.obolibrary.org/obo/MONDO_0005052|http://purl.obolibrary.org/obo/MONDO_0005265 |
| T8 | 1086-1098 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
| T9 | 1125-1132 | Disease | denotes | colitis | http://purl.obolibrary.org/obo/MONDO_0005292 |
| T10 | 1339-1342 | Disease | denotes | IBD | http://purl.obolibrary.org/obo/MONDO_0005052|http://purl.obolibrary.org/obo/MONDO_0005265 |
HP-phenotype
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 86-112 | Phenotype | denotes | inflammatory bowel disease | HP:0002037 |
| T2 | 114-141 | Phenotype | denotes | Inflammatory bowel diseases | HP:0002037 |
| T3 | 143-147 | Phenotype | denotes | IBDs | HP:0002037 |
| T4 | 1119-1132 | Phenotype | denotes | acute colitis | HP:0100282 |
NCBITAXON
| Id | Subject | Object | Predicate | Lexical cue | db_id |
|---|---|---|---|---|---|
| T1 | 1104-1109 | OrganismTaxon | denotes | mouse | 10088|10090 |
| T3 | 1200-1205 | OrganismTaxon | denotes | human | 9606 |
Anatomy-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 99-104 | Body_part | denotes | bowel | http://purl.obolibrary.org/obo/UBERON_0000160 |
| T2 | 127-132 | Body_part | denotes | bowel | http://purl.obolibrary.org/obo/UBERON_0000160 |
| T3 | 1280-1289 | Body_part | denotes | backbones | http://purl.obolibrary.org/obo/UBERON_0001130 |